Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner

Anesthesiology

Volumn 113, Issue 3, 2010, Pages 655-665

  Wang, Sho Ya ^a,b,c   Calderon, Joanna ^a,b,c   Wang, Ging Kuo ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; SODIUM CHANNEL NAV1.4; SODIUM CHANNEL NAV1.7; ANTIDEPRESSANT AGENT; SCN9A PROTEIN, HUMAN; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; THIOPHENE DERIVATIVE;

ANALGESIC ACTIVITY; ARTICLE; BINDING SITE; CHANNEL GATING; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; SODIUM CURRENT; WILD TYPE; CELL LINE; COMPARATIVE STUDY; GENETICS; MUTATION; PHYSIOLOGY;

ANTIDEPRESSIVE AGENTS; CELL LINE; HUMANS; MUTATION; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; THIOPHENES;

EID: 77957013000     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181e89a93     Document Type: Article

References (40)

1. Baldessarini RJ: Drugs and the treatment of psychiatric disorders: Depression and anxiety disorders, The Pharmacological Basis of Therapeutics, 10th edition. Edited by Hardman JG, Limbird LE, Gilman AG. New York, The McGraw-Hill Companies, Inc., 2001, pp 447-484
2. Müller N, Schennach R, Riedel M, Möller HJ: Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Rev Neurother 2008; 8:527-536
3. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM: Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008; 136:432-444
4. Westanmo AD, Gayken J, Haight R: Duloxetine: A balanced and selective norepinephrine-and serotonin-reuptake inhibitor. Am J Health Syst Pharm 2005; 62:2481-2490
5. Monks R, Merskey H: Psychotropic drugs, Textbook of Pain, 4th edition. Edited by Wall PD, Melzack R. New York, Churchill Livingstone, 1999, pp 1155-1186
6. Pancrazio JJ, Kamatchi GL, Roscoe AK, Lynch C 3rd: Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther 1998; 284:208-214
7. Bräu ME, Dreimann M, Olschewski A, Vogel W, Hempelmann G: Effects of drugs used for neuropathic pain management on tetrodotoxin-resistant Na+ currents in rat sensory neurons. ANESTHESIOLOGY 2001; 94:137-144
8. Gerner P, Wang GK: Mechanisms of tricyclic antidepressants in pain modulation, Comparing Preclinical Studies and Clinical Pain Management: Lost in Translation? Edited by Mao J. Hauppauge, New York, Nova Science Publishers, Inc., 2006, pp 189-206
9. Dick IE, Brochu RM, Purohit Y, Kaczorowski GJ, Martin WJ, Priest BT: Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain 2007; 8:315-324
10. Goldin AL: Resurgence of sodium channel research. Annu Rev Physiol 2001; 63:871-894
11. Wood JN, Baker M: Voltage-gated sodium channels. Curr Opin Pharmacol 2001; 1:17-21
12. Aldrich RW, Corey DP, Stevens CF: A reinterpretation of mammalian sodium channel gating based on single channel recording. Nature 1983; 306:436-441
13. Hille B: Local anesthetics: Hydrophilic and hydrophobic pathways for drug-receptor reaction. J Gen Physiol 1977; 69:497-515
14. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, Gribble FM, Woods CG: An SCN9A channelopathy causes congenital inability to experience pain. Nature 2006; 444:894-898
15. Drenth JP, Waxman SG: Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. J Clin Invest 2007; 117:3603-3609
16. Fertleman CR, Baker MD, Parker KA, Moffatt S, Elmslie FV, Abrahamsen B, Ostman J, Klugbauer N, Wood JN, Gardiner RM, Rees M: SCN9A mutations in paroxysmal extreme pain disorder: Allelic variants underlie distinct channel defects and phenotypes. Neuron 2006; 52:767-774
17. Cummins TR, Sheets PL, Waxman SG: The roles of sodium channels in nociception: Implications for mechanisms of pain. Pain 2007; 131:243-257
18. Martinez-Lavin M, Solano C: Dorsal root ganglia, sodium channels, and fibromyalgia sympathetic pain. Med Hypotheses 2009; 72:64-66
19. Ahern CA, Eastwood AL, Dougherty DA, Horn R: Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res 2008; 102:86-94
20. Wang SY, Mitchell J, Moczydlowski E, Wang GK: Block of inactivation-deficient Na+ channels by local anesthetics in stably transfected mammalian cells: Evidence for drug binding along the activation pathway. J Gen Physiol 2004; 124:691-701
21. Ramos E, O'leary ME: State-dependent trapping of flecainide in the cardiac sodium channel. J Physiol 2004; 560: 37-49
22. Grant AO, Chandra R, Keller C, Carboni M, Starmer CF: Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells. Biophys J 2000; 79:3019-3035
23. Klugbauer N, Lacinova L, Flockerzi V, Hofmann F: Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J 1995; 14:1084-1090
24. Wang GK, Russell C, Wang SY: Mexiletine block of wildtype and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels. J Physiol 2004; 554:621-633
25. Ragsdale DS, McPhee JC, Scheuer T, Catterall WA: Molecular determinants of state-dependent block of Na+ channels by local anesthetics. Science 1994; 265:1724-1728
26. Nau C, Wang GK: Interactions of local anesthetics with voltage-gated Na+ channels. J Membr Biol 2004; 201:1-8
27. Wang GK, Calderon J, Wang SY: State-and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine. Mol Pharmacol 2008; 73:940-948
28. Wright SN, Wang SY, Xiao YF, Wang GK: State-dependent cocaine block of sodium channel isoforms, chimeras, and channels coexpressed with the beta1 subunit. Biophys J 1999; 76:233-245
29. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981; 391:85-100
30. Wright SN, Wang SY, Kallen RG, Wang GK: Differences in steady-state inactivation between Na channel isoforms affect local anesthetic binding affinity. Biophys J 1997; 73: 779-788
31. Cota G, Armstrong CM: Sodium channel gating in clonal pituitary cells. The inactivation step is not voltage dependent. J Gen Physiol 1989; 94:213-232
32. Hille B: Classical mechanisms of block, Ion Channels of Excitable Membranes, 3rd edition. Sunderland, Massachusetts, Sinauer Associates Inc., 2001, pp 503-538
33. Cummins TR, Dib-Hajj SD, Waxman SG: Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci 2004; 24:8232-8236
34. Wang GK, Russell C, Wang SY: State-dependent block of voltage-gated Na+ channels by amitriptyline via the local anesthetic receptor and its implication for neuropathic pain. Pain 2004; 110:166-174
35. Catterall WA, Mackie K: Local anesthetics, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th edition. Edited by Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. New York, Macmillan Publishing Company, 2001, pp 367-384
36. Rolland J, Madage D, Ford J, Rogers M: Biophysical characterization of duloxetine activity on voltage-gated sodium channels involved in pain transmission (Abstract). Biophys J 2009; 96:252a
37. Wang GK, Russell C, Wang SY: State-dependent block of wild-type and inactivation-deficient Na+ channels by flecainide. J Gen Physiol 2003; 122:365-374
38. Zhou Y, MacKinnon R: Ion binding affinity in the cavity of the KcsA potassium channel. Biochemistry 2004; 43: 4978-4982
39. Sultan A, Gaskell H, Derry S, Moore RA: Duloxetine for painful diabetic neuropathy and fibromyalgia pain: Systematic review of randomised trials. BMC Neurol 2008; 8:29
40. Roth BL, Sheffler DJ, Kroeze WK: Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004; 3:353-359